FDA approves Johnson & Johnson’s IMAAVY as the first treatment ever cleared for warm autoimmune hemolytic anemia, marking a major step forward for patients

Johnson & Johnson announced that the U.S. FDA has approved IMAAVY for treating warm autoimmune hemolytic anemia, a rare and life-threatening autoantibody disease, in adults and pediatric patients aged 12 and older who are currently or have previously been treated with corticosteroids. The approval, which follows an earlier FDA Priority Review designation, marks the first time any therapy has been proven safe and effective specifically for treating this condition.

Karen Jones, president and executive director of wAIHA Warriors, said living with the condition often means dealing with relentless fatigue and the constant uncertainty of not knowing what the next day will bring. She said patients can cycle through periods where they begin to feel like themselves again, only for their hemoglobin to drop and the exhaustion to return, sending them back to where they started. She said this marks the first time the community has access to a treatment developed specifically for their disease.

Addressing a serious unmet need

In warm autoimmune hemolytic anemia, pathogenic IgG autoantibodies attach to red blood cells and destroy them, resulting in severe anemia, profound fatigue, and a significantly elevated risk of illness and death. Until now, treatment options were limited to corticosteroids and immunosuppressants, therapies that suppress the immune system broadly rather than specifically targeting the IgG autoantibodies driving the disease.

David Kuter, M.D., D.Phil., a distinguished physician at Massachusetts General Hospital and professor of medicine at Harvard Medical School, said the Phase 2/3 ENERGY study shows that targeting pathogenic IgG can meaningfully shift the treatment approach for this condition. He said more patients treated with IMAAVY achieved a durable hemoglobin response compared with those on placebo, meaning their red blood cell levels rose and stayed elevated. He said the approval gives patients access to a therapy with a proven safety profile that targets the autoantibodies actually driving the disease.

Clinical evidence summary

The primary endpoint of the Phase 2/3 ENERGY study was durable hemoglobin response, a rigorous measure reflecting meaningful, sustained increases in hemoglobin over time. In the randomized, placebo-controlled trial, roughly three times as many patients receiving the approved dose of IMAAVY achieved durable hemoglobin levels compared with placebo by week 24. Patients in the treatment group also showed a mean hemoglobin increase of 1 g/dL by week 1. IMAAVY was additionally linked to a 3.5-point higher mean FACIT-Fatigue score compared with placebo at week 24, with higher scores indicating less fatigue. In the ENERGY study, IMAAVY’s safety profile was consistent with its established profile in generalized myasthenia gravis. The most common side effects, occurring in 10 percent or more of patients with warm autoimmune hemolytic anemia treated with IMAAVY, were peripheral edema, diarrhea, and fever.

---

---

Related Topics and Keywords

autoimmune hemolytic anemia, FDA, hemolytic anemia, IMAAVY, Johnson & Johnson's, ohnson & Johnson's